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Abstract. Tubulointerstitial fibrosis is a common end point 
of chronic kidney diseases, and preventing its progression is 
key to avoiding renal failure. Transforming growth factor‑β 
(TGF-β) and associated molecules promote tubulointer-
stitial fibrosis; however, effective therapies targeting these 
molecules have yet to be developed. Lysyl oxidase‑like 2 
(LOXL2), which is involved in invasive growth and metas-
tasis of malignant neoplasms, has recently been reported to 
serve a key role in hepatic and pulmonary fibrosis. However, 
little is currently known regarding LOXL2 expression in 
the kidney and its involvement in tubulointerstitial fibrosis. 
The present study evaluated LOXL2 expression in human 
and mouse kidney tissues, as well as in cultured renal cells. 
LOXL2 protein expression was detected in glomerular capil-
lary loops and tubular epithelial cells in human and mouse 
kidneys. Glomerular LOXL2 was localized to the cytoplasm 
of podocytes, as determined by double immunofluorescence 
microscopy using a podocyte marker (synaptopodin). This 
result was supported by western blot analysis, which demon-
strated that LOXL2 protein expression is present in cultured 
human podocytes and HK‑2 human proximal tubular cells. In 
addition, the mRNA and protein expression levels of LOXL2 
were higher in a mouse model of tubulointerstitial fibrosis 
compared with in control mice. In addition, immunohisto-
chemistry results demonstrated that LOXL2 is present in the 
fibrous interstitium and infiltrating mononuclear cells in a 
mouse model of tubulointerstitial fibrosis. The present study 
demonstrated that LOXL2 is expressed in compartments of 
renal tissue, where it appears to contribute to the progression 
of tubulointerstitial fibrosis.
Introduction
Tubulointerstitial fibrosis is a common end point of diabetic 
nephropathy, allograft rejection and various glomerulone-
phritides. Therefore, preventing tubulointerstitial fibrosis is an 
important strategy in the treatment of chronic kidney diseases.
Members of the lysyl oxidase (LOX) family [e.g., LOX and 
LOX‑like (LOXL)1‑4] are responsible for the cross‑linking of 
collagen and elastin in the extracellular matrix through their 
copper‑dependent amine oxidase activity. In addition, LOX 
family members exhibit various functions in cell proliferation, 
tumor invasion and metastasis, and organ development (1). 
LOXL2 is the most thoroughly studied of the LOX family 
members. Its expression is associated with tumor cell 
differentiation in colon and esophageal carcinoma (2), and 
proliferation, migration and invasion of human hepatocel-
lular carcinoma cells (3). Increased LOXL2 expression is also 
associated with poor survival in squamous cell carcinoma of 
the larynx and lung (4), and appears to serve a role in the meta-
static potential of breast (5) and gastric carcinoma (6). Potential 
mechanisms underlying the effects of LOXL2 include fibro-
blast activation in the tumor microenvironment (7), induction 
of epithelial‑mesenchymal transition in tumor cells (5), and 
matrix remodeling via regulation of tissue inhibitor of metal-
loproteinase‑1 and matrix metalloproteinase‑9 (8).
The contribution of LOXL2 to benign fibrosing diseases 
has been studied in several organs. Previous studies have 
indicated that LOXL2 expression is associated with hepatic 
fibrosis in Wilson's disease, primary biliary cirrhosis (9) and 
hepatocellular carcinoma (10). Elevated serum LOXL2 levels 
are also associated with disease progression in idiopathic 
pulmonary fibrosis (11), and LOXL2 upregulation is associ-
ated with scar formation following glaucoma surgery (12).
An inhibitory monoclonal antibody to LOXL2 has been 
developed; AB0023 binds to human and mouse LOXL2, and 
AB0024 (simtuzumab) is its humanized form. The antifibrotic 
effects of AB0023, AB0024 and other inhibitory antibodies 
have been determined in several organs. For example, in 
a rabbit model of glaucoma surgery, AB0023 attenuated 
postoperative fibrosis (12). In BALB/c mice, AB0023 attenu-
ated tetrachloride‑induced hepatic fibrosis and decreased 
phosphorylated‑Smad3 signaling. In C57BL/6 mice, AB0023 
attenuated high‑dose bleomycin‑induced pulmonary fibrosis, 
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and this effect was mediated by inhibiting fibroblast recruitment 
and activation (13). Based on the results of previous animal 
experiments, clinical trials of simtuzumab for human fibrosing 
diseases have been performed. The target diseases include 
advanced liver fibrosis due to human immunodeficiency virus 
and hepatitis C virus infection (14), and idiopathic pulmonary 
fibrosis (clinicaltrials.gov/ct2/show/NCT01769196).
Although fibrosis is a clinically important pathological 
process in kidney disease, little is currently known regarding the 
expression of LOXL2 in renal tissue and its contribution to the 
development of renal tubulointerstitial fibrosis. In the present 
study, the expression of LOXL2 in normal kidney was evalu-
ated in tissues and cell lines. In addition, to evaluate its possible 
profibrotic role, LOXL2 expression was evaluated in the kidneys 
of mice following the induction of tubulointerstitial fibrosis.
Materials and methods
Renal cell culture. For the in vitro study, human podocytes and 
the most widely used proximal and distal tubular epithelial cell 
lines were selected. Immortalized human proximal tubular cells 
(HK‑2 cells) were purchased from the American Type Culture 
Collection (Manassas, VA, USA) and canine tubular cells 
(MDCK cells; cat. no. 10034) were purchased from the Korean 
Cell Line Bank (Seoul, South Korea). HK‑2 cells were cultured 
in Dulbecco's modified Eagle's medium (DMEM)/Nutrient 
Mixture F‑12 (Gibco; Thermo Fisher Scientific, Inc., Waltham, 
MA, USA) and 10% fetal bovine serum (FBS; Gibco; Thermo 
Fisher Scientific, Inc.). MDCK cells were cultured in DMEM 
(Gibco; Thermo Fisher Scientific, Inc.). Conditionally immor-
talized human podocytes were provided by Dr Moin A. Saleem 
(University of Bristol, Bristol, UK) and Dr Jun Oh (University 
Medical Center Hamburg‑Eppendorf, Hamburg, Germany). 
The podocytes were grown in RPMI‑1640 medium (Gibco; 
Thermo Fisher Scientific, Inc.), 10% FBS and insulin‑trans-
ferrin‑selenium supplement (Gibco; Thermo Fisher Scientific, 
Inc.) at 33˚C to activate the SV40 large T antigen. The cells were 
then cultured at 37˚C for 2 weeks to induce differentiation (15), 
which was confirmed by western blotting for synaptopodin 
(data not presented).
Animal model of tubulointerstitial fibrosis. Male CD1 mice of 
8 weeks of age (Orient Bio, Inc., Seongnam, South Korea) were 
used for the animal experiments. Mice were housed at 20˚C 
with a 12‑h light/dark cycle and free access to rodent chow and 
water. Tubulointerstitial fibrosis was induced in 4 mice (mean 
body weight, 42.5 g) by intraperitoneal injection of folic acid 
(240 µg/g body weight), according to previously described 
methods (16,17). The folic acid solution was prepared by 
dissolving folic acid powder (Sigma‑Aldrich; Merck KGaA, 
Darmstadt, Germany) in 0.3 M NaHCO3. Control CD1 mice 
(n=4; mean body weight, 43.1 g) were intraperitoneally 
injected with the same amount of vehicle (NaHCO3). After 
4 weeks, the mice were sacrificed, and the kidneys were 
harvested. Fresh frozen tissues were stored at ‑70˚C subsequent 
to instant freezing in liquid nitrogen. Additional tissues were 
fixed in 4% formaldehyde for 24 h at room temperature and 
embedded in paraffin overnight at 55‑65˚C using an automatic 
tissue processer (EFTP‑FAST 360; Intelsint, Turin, Italy). 
The present study was approved by the Institutional Animal 
Care and Use Committee of Yonsei University Health System 
(Seoul, South Korea).
Western blot analysis of LOXL2 expression. HK‑2 cells, 
MDCK cells and differentiated human podocytes were lysed 
in radioimmunoprecipitation assay buffer (Biosesang, Inc., 
Seongnam, Korea) containing protease inhibitor cocktail 
(Roche Diagnostics, Indianapolis, IN, USA). The samples 
were centrifuged at 15,871 x g for 30 min at 4˚C, and protein 
concentration was measured using the bicinchoninic acid 
protein assay kit (Thermo Scientific, Inc.) according to the 
manufacturer's protocol. Protein samples (50 µg) were sepa-
rated by 10% SDS‑PAGE for 2 h at 100 V and were then 
transferred to a polyvinylidene fluoride membrane. After 
blocking with 3% skim milk for 1 h at room temperature, the 
membrane was incubated with the following primary anti-
bodies overnight at 4˚C: Anti‑synaptopodin (cat. no. sc‑21537; 
1:2,000; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), 
anti‑LOXL2 (cat. no. ab96233; 1:500; Abcam, Cambridge, MA, 
USA) and anti‑LOXL2, which has epitope homology to canine 
species (cat. no. TA335061; 1:100; OriGene Technologies, 
Inc., Rockville, MD, USA). The membrane was then washed 
with Tris‑buffered saline containing 0.1% Tween‑20 and was 
incubated with horseradish peroxidase‑labeled secondary anti-
bodies (cat. no. sc‑2020; 1:5,000; Santa Cruz Biotechnology, 
Inc.; and cat. no. K4003; 1:5,000; Dako; Agilent Technologies, 
Inc., Santa Clara, CA, USA) for 1 h at room temperature. 
Protein bands were visualized using Pierce Enhanced 
Chemiluminescence Western Blotting Substrate (Thermo 
Fisher Scientific, Inc.). After stripping the membrane with 
Restore Western Blot Stripping Buffer (Thermo Fisher 
Scientific, Inc.) for 15 min at room temperature, the membrane 
was incubated with an anti‑β‑actin antibody (cat. no. sc‑47778; 
1:2,000; Santa Cruz Biotechnology, Inc.), which was used as a 
loading control. In addition, fresh frozen kidneys from vehicle 
or folic acid‑injected mice were homogenized, and western blot-
ting was performed in a similar manner. Semi‑quantification 
of the bands was performed by densitometry using Image J 
software (version 1.50i; National Institutes of Health, Bethesda, 
MD, USA).
Immunohistochemistry and immunofluorescence analysis 
of LOXL2 in human and mouse kidneys. LOXL2 expression 
in human and mouse kidneys was evaluated by immunohis-
tochemistry and Olympus BX53 light microscope (Olympus 
Corporation, Tokyo, Japan). Paraffin‑embedded human 
kidney tissues from 4 patients were obtained from the surgical 
pathology archive of the Department of Pathology, Yonsei 
University, Gangnam Severance Hospital (Seoul, South Korea). 
These tissues were obtained from a non‑neoplastic portion 
of a nephrectomy specimen of a renal tumor. The use of 
archived human tissue was approved by the institutional review 
board of Yonsei University, Gangnam Severance Hospital. 
The paraffin‑embedded kidneys from the aforementioned 
vehicle‑ and folic acid‑injected mice were also used for immu-
nohistochemical analysis of LOXL2 expression.
Human and mouse kidney tissues were cut into 4‑µm 
sections, deparaffinized, and rehydrated using xylene and 
ethanol. Antigen retrieval was conducted by microwaving the 
tissue sections in 0.01 M sodium citrate buffer (pH 6.0) for 
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10 min. Endogenous peroxidase activity was blocked with 0.3% 
hydrogen peroxidase for 10 min. The tissue sections were then 
incubated overnight with a primary antibody against LOXL2 
(cat. no. ab96233; 1:1,000; Abcam) at 4˚C, followed by incuba-
tion with a horseradish peroxidase‑labeled secondary antibody 
(cat. no. K4003; prediluted; Dako; Agilent Technologies, Inc.) 
for 1 h at room temperature. The protein was visualized using 
the chromogen diaminobenzidine.
Double immunofluorescence staining for LOXL2 along 
with synaptopodin was performed in a similar manner. 
Sections were incubated with the primary antibody against 
LOXL2 (1:100) for 4 h at room temperature, followed by 
incubation with a Texas Red‑conjugated anti‑rabbit immuno-
globulin G (cat. no. TI‑1000; 1:50; Vector Laboratories, Inc., 
Burlingame, CA, USA) overnight at 4˚C. Subsequently, the 
tissue sections were incubated with a primary antibody against 
synaptopodin (cat. no. 65294; 1:50; Progen Biotechnik GmbH, 
Heidelberg, Germany) for 4 h at room temperature, followed 
by incubation with fluorescein isothiocyanate‑conjugated 
anti‑mouse secondary antibody (cat. no. FI‑2000; 1:50; Vector 
Laboratories, Inc.) overnight at 4˚C.
Reverse transcription‑quantitative polymerase chain reaction 
(RT‑qPCR) analysis of LOXL2 expression. The mRNA expres-
sion levels of LOXL2 in renal cells and fresh frozen kidneys 
from the vehicle‑ or folic acid‑injected mice were analyzed 
by RT‑qPCR. RNA was extracted using the RNeasy Mini kit 
(Qiagen GmbH, Hilden, Germany) according to the manufac-
turer's protocol, and the RNA was reverse transcribed using 
the QuantiTect Reverse Transcription kit (Qiagen GmbH) 
according to the manufacturer's protocol. PCR amplifica-
tion was performed using TaqMan Gene Expression Master 
Mix and an ABI 7900 HT real‑time PCR system (Applied 
Biosystems; Thermo Fisher Scientific, Inc.) with the following 
thermal cycle: 2 min at 50˚C for uracil DNA‑glycosylase 
enzyme incubation and 10 min at 95˚C for AmpiTaq Gold 
enzyme activation, followed by 40 cycles of 15 sec at 95˚C 
and 1 min at 60˚C. TaqMan primer/probes for mouse LOXL2 
(cat. no. Mm00804740_m1) and ribosomal 18S RNA 
(cat. no. Mm03928990_g1) were purchased from Applied 
Biosystems (Thermo Fisher Scientific, Inc.). Expression was 
calculated using the 2-ΔΔCq method (18).
Statistical analysis. Quantitative analysis was performed for the 
western blotting and RT‑qPCR results. Folic acid‑injected and 
vehicle‑treated control groups were compared (n=4 mice/group). 
Data are expressed as the mean ± standard deviation and were 
compared using the Mann‑Whitney U test. The analyses were 
performed using GraphPad Prism 6 for Windows (GraphPad 
Software, Inc., La Jolla, CA, USA). P<0.05 was considered to 
indicate a statistically significant difference.
Results
LOXL2 protein expression in human and mouse kidneys. 
Immunohistochemistry results demonstrated that LOXL2 
protein was expressed in the glomeruli and tubular epithelial 
cells in human kidneys (Fig. 1A). In the glomeruli, LOXL2 
staining was observed along the outer surface of capillary loops. 
In the tubular epithelial cells, LOXL2 staining was cytoplasmic 
with no nuclear or membranous staining observed (Fig. 1A). 
Proximal and distal tubules expressed LOXL2; however, more 
prominent staining was detected in distal tubular epithelial 
cells. In the mouse kidney, LOXL2 staining was also observed 
in the glomeruli and tubular epithelial cells (Fig. 1B).
To determine the precise location of LOXL2 expression, 
double immunofluorescence microscopy, using the podocyte 
marker synaptopodin, was performed in the human kidney. 
LOXL2 expression was detected in the cytoplasm of podocytes, 
where synaptopodin expression was also observed (Fig. 2).
LOXL2 expression in cultured cells. In cultured cell lines, 
LOXL2 expression was detected in human podocytes and 
HK‑2 cells, as determined by western blot analysis, which 
supported the aforementioned results. However, MDCK cells, 
which are tubular cells derived from canine kidney, did not 
express LOXL2 (Fig. 3).
LOXL2 expression in a mouse model of tubulointerstitial 
fibrosis. Folic acid injection successfully induced diffuse 
renal tubulointerstitial fibrosis in mice (Fig. 4A and B). 
Immunohistochemistry analysis of LOXL2 demonstrated 
strong immunoreactivity in infiltrating inflammatory cells and 
Figure 1. LOXL2 expression in human and mouse kidneys. Results of immu-
nohistochemistry revealed that LOXL2 expression is present in glomeruli 
and tubular epithelial cells in the (A) human and (B) mouse kidney samples. 
In the glomeruli, LOXL2 staining was observed along glomerular capillary 
loops (arrow). In the tubular epithelial cells, LOXL2 staining was observed 
in the cytoplasm (arrow heads). The staining was more prominent in distal 
tubules (black arrow head) than in proximal tubules (open arrow head). 
Magnification, x400. LOXL2, lysyl oxidase‑like 2.
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the interstitium, in addition to glomerular and tubular expres-
sion (Fig. 4C). RT‑qPCR analysis indicated that the mRNA 
expression levels of LOXL2 were significantly increased 
in folic acid‑injected mice compared with vehicle‑injected 
controls (P=0.029; Fig. 4D). In addition, as determined by 
western blotting, the protein expression levels of LOXL2 
were increased in folic acid‑injected mice compared with 
vehicle‑injected mice (P=0.023; Fig. 4E).
Discussion
Tubulointerstitial fibrosis occurs during the progression of all 
chronic kidney diseases. Preventing tubulointerstitial fibrosis, 
regardless of its etiology, is important in the preservation of 
renal function. TGF‑β is a key molecule in the development 
and progression of tubulointerstitial fibrosis. Activators of 
latent TGF-β include integrin αvβ6; downstream signal 
transduction molecules of the TGF‑β signaling pathway, 
such as members of the Smad family and mitogen‑activated 
protein kinases; and upstream signal transduction molecules. 
Contributing signal transduction pathways and mechanisms 
include the Wnt/β‑catenin pathway, platelet‑derived growth 
factors, epithelial‑mesenchymal transition and autophagy (19). 
Recently, knowledge regarding the mechanisms underlying the 
pathogenesis of tubulointerstitial fibrosis has increased, and an 
animal study regarding its prevention has produced promising 
results (20). However, few therapeutic agents for clinical use 
have been developed. Therefore, a better understanding of 
the molecular mechanisms is required for the development of 
novel treatment strategies for tubulointerstitial fibrosis.
LOXL2, which serves a role in cancer metastasis, is also 
involved in organ fibrosis. Previous studies have demonstrated the 
involvement of LOXL2 in hepatic and pulmonary fibrosis, and 
clinical trials have evaluated a LOXL2‑specific inhibitor (9,11-13). 
Although the clinical implications of kidney fibrosis are substan-
tial, little is currently known regarding LOXL2 expression in 
this organ, and the role of LOXL2 in tubulointerstitial fibrosis 
remains to be elucidated. Therefore, the present study evaluated 
LOXL2 expression in cellular compartments of the kidney and 
its possible contribution to tubulointerstitial fibrosis.
A previous study reported that LOXL2 expression in HK‑2 
cells was increased by hypoxia and hyperglycemia, and this 
alteration was associated with hypoxia inducible factor‑1α (21). 
The present study revealed that LOXL2 is primarily expressed 
in tubular cells in the kidney, particularly in distal tubular 
cells. There are numerous mechanisms by which tubular 
epithelial cells initiate or contribute to the progression 
of tubulointerstitial fibrosis. Following hypoxic, toxic or 
immunological insult‑induced injury, tubular cells secrete 
chemoattractants to induce interstitial inflammation (22). 
TGF-β1 and type III TGF‑β1 receptor have critical roles in 
the linkage of inflammation and fibrosis via the TGF‑β/Smad3 
signaling pathway (23). Epithelial‑mesenchymal transition may 
also contribute to interstitial fibrosis by providing a source of 
fibrogenic myofibroblasts (24). Tubular epithelial cells lose 
cell‑cell adhesion and acquire myofibroblast properties through 
the induction of TGF‑β. Other signaling pathways and cellular 
components, including autophagy, Wnt/β‑catenin signaling and 
integrin‑linked kinase, are also involved in this process (25,26). 
Figure 2. Double immunofluorescence microscopy analysis of LOXL2 in 
human podocytes. In the glomeruli, (A) LOXL2 and (B) the podocyte‑specific 
marker synaptopodin were (C) colocalized in podocyte cytoplasm. 
Magnification, x400. LOXL2, lysyl oxidase‑like 2.
Figure 3. Western blot analysis of LOXL2 expression in cultured proximal 
tubular cells and podocytes. LOXL2 protein levels in cultured human 
proximal tubular cells (HK‑2), canine tubular cells (MDCK) and immor-
talized human podocytes were evaluated by western blotting. The results 
demonstrated that LOXL2 is expressed in HK‑2 cells and podocytes, but 
not in MDCK cells. Another group of MDCK cells was reacted with canine 
LOXL2 antibody and exhibited no expression. Lane 1, human podocyte; 
lane 2, HK‑2 cell; lane 3, MDCK cell; lane 4, MDCK cell (canine antibody). 
LOXL2, lysyl oxidase‑like 2.
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Although the underlying mechanisms remain unclear, it is 
highly probable that tubular epithelial cells have a critical role 
in the progression of tubulointerstitial fibrosis. The present 
observation that LOXL2 is expressed in tubular epithelial cells 
suggests a role for LOXL2 in TGF‑β‑mediated tubulointerstitial 
fibrosis. This hypothesis is supported by the increased LOXL2 
mRNA and protein levels detected in the kidneys of mice with 
folic acid‑induced tubulointerstitial fibrosis.
The association between LOXL2 and TGF‑β has been 
investigated in numerous studies. Sethi et al demonstrated 
that the expression of LOX family genes, including LOXL2, 
is induced by TGF‑β1, TGF-β2 and TGF‑β3, and is mediated 
by canonical Smad signaling and noncanonical signaling path-
ways (27). Voloshenyuk et al reported that TGF‑β1 upregulates 
LOX expression in cardiac fibroblasts, and this phenomenon 
may be prevented by inhibiting Smad3 (28). Conversely, an 
inhibitory monoclonal antibody against LOXL2 has been 
reported to decrease fibroblast activation and TGF‑β signaling, 
suggesting that LOXL2 serves a role in activating TGF‑β (13). 
Direct suppression of TGF‑β was not successful in preventing 
renal fibrosis due to of the diversity of TGF‑β isoforms and 
their signaling pathways (29). Therefore, it may be suggested 
that LOXL2, and other molecules involved in TGF‑β signaling 
pathways, should be considered as therapeutic targets.
The expression of LOXL2 in infiltrating inflammatory 
cells detected in the present study is interesting considering 
that infiltrating macrophages also express TGF‑β (30). This 
finding suggested that the potential mechanisms underlying 
the effects of LOXL2 in tubulointerstitial fibrosis are complex.
The present study also detected LOXL2 expression in 
podocytes, which may have clinical significance. Considerable 
evidence supports the role of podocyte injury as a key factor in 
the pathogenesis of focal segmental glomerulosclerosis (31-33). 
Podocyte detachment is also an important pathogenic mecha-
nism in the progression of diabetic nephropathy (34), which is 
characterized by nodular glomerulosclerosis. Considering the 
Figure 4. LOXL2 expression in a mouse model of tubulointerstitial fibrosis. Compared with in (A) vehicle‑treated control mice, (B) diffuse tubulointerstitial 
fibrosis was induced 4 weeks after intraperitoneal injection of folic acid in CD1 mice. (C) Immunohistochemistry analysis detected LOXL2 protein expression 
in the fibrous interstitium and infiltrating mononuclear cells (arrows) in folic acid‑injected mice. (D) mRNA expression levels of LOXL2 were markedly 
increased in folic acid‑injected mice compared with vehicle‑treated mice. (E) Results of a western blot analysis detected a significant increase in LOXL2 
protein expression in folic acid‑injected mice. Magnification, x400. *P<0.05. LOXL2, lysyl oxidase‑like 2.
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profibrogenic function of LOXL2 in other organs, it is reason-
able to hypothesize that podocyte LOXL2 may contribute to 
the progression of glomerulosclerosis.
In conclusion, LOXL2, which is a protein involved in extra-
cellular matrix remodeling and organ fibrosis, is expressed 
in renal tubular epithelial cells and podocytes. Improved 
understanding regarding the function of LOXL2 in the kidney 
may strengthen knowledge of the pathophysiology of tubuloin-
terstitial fibrosis and glomerulosclerosis, and may lead to the 
discovery of novel therapeutic targets.
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